Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$58.53 USD
-0.71 (-1.20%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $58.40 -0.13 (-0.22%) 6:40 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Balance Sheet
Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 336 | 363 | 741 | 368 | 421 |
Receivables | 234 | 231 | 91 | 98 | 59 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 128 | 100 | 54 | 61 | 29 |
Other Current Assets | 49 | 45 | 40 | 28 | 33 |
Total Current Assets | 746 | 739 | 926 | 555 | 543 |
Net Property & Equipment | 75 | 76 | 9 | 11 | 11 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 4 | 44 | 155 | 0 | 0 |
Intangibles | 890 | 956 | 0 | 0 | 0 |
Deposits & Other Assets | 18 | 27 | 14 | 15 | 12 |
Total Assets | 1,733 | 1,842 | 1,104 | 580 | 566 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 12 | 18 | 2 | 2 | 6 |
Current Portion Long-Term Debt | 0 | 13 | 89 | 397 | 20 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 101 | 97 | 24 | 20 | 56 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 3 | 2 | 2 | 4 |
Total Current Liabilities | 112 | 131 | 117 | 421 | 86 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 2 | 3 | 4 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1,499 | 1,493 | 787 | 0 | 383 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 38 | 46 | 1 | 3 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,649 | 1,672 | 907 | 429 | 474 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2 | 27 | 256 | 625 | 695 |
Retained Earnings | 91 | 143 | -59 | -475 | -604 |
Other Equity | -9 | -1 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 84 | 170 | 197 | 151 | 92 |
Total Liabilities & Shareholder's Equity | 1,733 | 1,842 | 1,104 | 580 | 566 |
Total Common Equity | 84 | 170 | 197 | 151 | 92 |
Shares Outstanding | 132.10 | 135.20 | 140.70 | 135.10 | 146.50 |
Book Value Per Share | 0.63 | 1.26 | 1.40 | 1.12 | 0.63 |
Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 529 | 463 | 336 | 483 | 348 |
Receivables | 215 | 196 | 234 | 217 | 246 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 159 | 169 | 128 | 129 | 132 |
Other Current Assets | 85 | 46 | 49 | 49 | 39 |
Total Current Assets | 988 | 874 | 746 | 879 | 766 |
Net Property & Equipment | 75 | 78 | 75 | 75 | 75 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 1 | 4 | 13 | 24 |
Intangibles | 854 | 872 | 890 | 907 | 928 |
Deposits & Other Assets | 52 | 17 | 18 | 18 | 18 |
Total Assets | 1,969 | 1,842 | 1,733 | 1,893 | 1,810 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 13 | 12 | 19 | 10 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 118 | 118 | 101 | 95 | 105 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 1 |
Total Current Liabilities | 133 | 132 | 112 | 115 | 116 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 14 | 0 | 0 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1,503 | 1,501 | 1,499 | 1,498 | 1,496 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 31 | 38 | 28 | 45 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,680 | 1,664 | 1,649 | 1,643 | 1,659 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 31 | 12 | 2 | 26 | 12 |
Retained Earnings | 261 | 167 | 91 | 222 | 140 |
Other Equity | -2 | -1 | -9 | 1 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 289 | 178 | 84 | 249 | 151 |
Total Liabilities & Shareholder's Equity | 1,969 | 1,842 | 1,733 | 1,893 | 1,810 |
Total Common Equity | 289 | 178 | 84 | 249 | 151 |
Shares Outstanding | 127.20 | 127.00 | 132.10 | 131.90 | 131.60 |
Book Value Per Share | 2.28 | 1.40 | 0.63 | 1.89 | 1.15 |